NCT00798538View on ClinicalTrials.gov

Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM)

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
BuprenorphineHIVDrug AbuseDrug AddictionDrug DependenceDrug Use DisordersDrug Use DisorderSubstance AbuseOpiate AddictionSubstance-related Disorders
Interventions
OTHER

Services will be provided at one site

Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..

OTHER

Services remain dispersed; i.e., not centralized to one-location or provider.

Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.

Trial Locations (1)

06510

Yale AIDS Program, New Haven

All Listed Sponsors
collaborator

Waterbury Hospital

UNKNOWN

collaborator

Health Resources and Services Administration (HRSA)

FED

collaborator

The New York Academy of Medicine

OTHER

lead

Yale University

OTHER

NCT00798538 - Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) | Biotech Hunter | Biotech Hunter